Nobel Biocare Implants: Cost and Who the Warranty Covers

Most patients meet the name Nobel Biocare on a treatment quote rather than in a brochure, and the two questions that follow are always the same: what does it cost, and what happens if it fails. This page answers both with documents rather than adjectives. Every technical value below comes either from a regulatory filing, from the manufacturer's own published terms, or from peer-reviewed literature, and the findings that do not flatter the brand sit in the same page as the ones that do. The implant system comparison table carries the equivalent specifications for the lines we place side by side.

/ Who owns Nobel Biocare and where Nobel Biocare implants are made

The query nobel biocare implant country returns a single-word answer almost everywhere, and the single-word answer is wrong in every version. Three countries hold three distinct roles.

Switzerland holds the headquarters. The legal entity in Kloten, near Zurich, is Nobel Biocare Services AG, and it is the registered owner of the brand's trademarks. The FDA record matches: clearance K211109 for the N1 TiUltra TCC Implant System, decided 21 December 2021, lists Nobel Biocare Services AG in Kloten, Switzerland.

Sweden holds manufacturing and the regulatory filings. Clearance K202344 for TiUltra Implants and Xeal Abutments, decided 16 November 2020, lists Nobel Biocare AB at Västra Hamngatan 1 in Gothenburg. So does K243834 for the NobelZygoma TiUltra system in August 2025, and so does the most recent clearance, K252197, decided 18 February 2026. This is the continuation of Per-Ingvar Brånemark's Gothenburg lineage, not a marketing reference to it.

The United States holds ownership. Danaher acquired Nobel Biocare in 2014 and spun its dental segment out as Envista Holdings in 2019. Envista is headquartered in Brea, California, trades on the New York Stock Exchange under NVST, and filed its most recent quarterly report with the Securities and Exchange Commission on 5 August 2026. A company that files 10-Qs and trades publicly is independent and verifiable, which is why the ownership line on this page can be stated without hedging.

For a patient, the practical consequence is narrow but real: a system whose regulatory filings, trademarks and corporate accounts are all public is a system whose claims you can check yourself, which is not true of every brand you will be quoted.

/ What a Nobel Biocare implant is actually made of

Several pages state that Nobel Biocare implants are made from both grade 4 and grade 5 titanium. The regulatory record does not support that, and the distinction matters because the two are not variants of one material.

The materials row in FDA 510(k) summary K202344 reads verbatim: "The material used for all devices is commercially pure titanium." Commercially pure titanium is unalloyed by definition. What is commonly called grade 5 is Ti-6Al-4V, an alloy containing roughly 6% aluminium and 4% vanadium. The manufacturer's instructions for use specify the fixture as grade 4 and publish the composition: titanium balanced with a maximum of 0.50 wt.% iron, 0.40 wt.% oxygen, 0.08 wt.% carbon, 0.05 wt.% nitrogen and 0.015 wt.% hydrogen.

The alloy does exist in the box, just not in the fixture. Cover screws, clinical screws and surgical instruments are made from Ti-6Al-4V. That is why the contraindication paragraph in the manuals lists both commercially pure titanium and the alloy: it covers everything supplied, not the implant body alone. Reading that line as evidence of an alloy fixture line is an easy mistake and a documented one.

The comparison worth drawing is that grade 4 commercially pure titanium is the shared baseline across the field rather than a differentiator, so material is not where systems separate. They separate on surface treatment and connection geometry, and both are covered below. If you want the mechanics of what sits inside the fixture, our dental implant screw explainer covers it separately.

/ TiUnite and TiUltra are two surfaces, and the long-term data belong to the older one

This is the single most important line in the Nobel Biocare spec sheet, and it appears on almost no patient-facing page.

TiUnite is an anodised, moderately rough surface introduced in 2000. Every 10, 15 and 20-year survival figure published for this brand belongs to it, because it was the surface in the mouths being followed.

TiUltra is the current line, cleared by the FDA on 16 November 2020 under K202344. The difference is not naming. In the manufacturer's own comparison table filed with that clearance, TiUltra is a multi-level anodisation whose roughness and oxide thickness change gradually from collar to body, while standard TiUnite is described as a single-level surface.

The second difference is wettability, and it is documented rather than claimed. The same FDA table carries a "surface preservation" row reading "hydrophilic surface, sodium dihydrogen phosphate dihydrate and magnesium chloride hexahydrate salt" for TiUltra, and "N/A" for the TiUnite predicate devices. The manufacturer's own instructions for use draw the same line: the TiUltra materials entry lists the water-soluble salt layer, the TiUnite entry does not, and the two surfaces carry separate contraindication lists.

The practical consequence is that a quote reading only "Nobel Biocare" does not tell you which surface you are getting. The instructions for use issued on 18 February 2026 still name products in the paired form "TiUltra/TiUnite", meaning both surfaces remain on sale. Ask for the product code, not the brand name, and get the answer in writing before treatment rather than after.

/ The TiUltra surface, measured: three zones on one fixture

Surface roughness is rarely given as a number on patient pages, yet the manufacturer publishes it in full in its FDA filing. TiUltra is specified in three zones: at the collar, areal roughness Sa is 0.5 ± 0.3 micrometres with an oxide thickness of 0.166 ± 0.008 micrometres; at the transition, Sa is 0.8 ± 0.3 micrometres with a thickness of 7.5 ± 0.3 micrometres; at the body, Sa is 1.5 ± 0.4 micrometres with a thickness of 12.0 ± 1.2 micrometres.

Those numbers only mean something against a reference band. The standing review of implant surface topography defines the moderately rough band as Sa 1.0 to 2.0 micrometres and reports it as the range producing the strongest bone response (PubMed 15543910). The TiUltra body sits at 1.5 micrometres, inside that band. The collar sits at 0.5 micrometres, deliberately well below it, which is the design intent of a graded surface: rough where bone is wanted, smoother where soft tissue and plaque control matter.

For comparison, the same filing lists TiUnite in its single-level form at Sa 1.2 ± 0.5 micrometres with an oxide thickness of 12.5 ± 2.5 micrometres. So the body roughness of the two surfaces is close; the redesign is concentrated in the collar zone and in the salt layer.

The caveat from the same review belongs here, because a number is not an outcome: the clinical advantages of moderately rough surfaces over smoother or rougher ones are small and often not statistically significant. Roughness is a measurable physical property. What happens in your jaw also depends on bone quality, loading protocol and maintenance, which our implant healing timeline sets out step by step.

/ What the published survival data actually says

Nobel Biocare has one of the deepest long-term literatures in the field, and the figures come from several different scales rather than one flattering study.

The strongest brand-specific record is a meta-analysis of implants with the anodised TiUnite surface. It screened 32,519 publications and included 106 prospective studies, each with at least 20 patients and at least 12 months of follow-up after loading. Survival at one year was 99.50% at implant level and 99.12% at patient level. At ten years it was 95.14% at implant level and 91.50% at patient level. Mean marginal bone change was 0.409 mm at one year and 0.886 mm at five years at implant level (PubMed 28708905).

Single-centre cohorts report higher figures, and the difference is methodological rather than contradictory. A prospective Swedish cohort followed 133 implants in 46 patients at one county clinic for 20 years and reported 94.7% survival. Seven implants were lost, four of them in the same patient, and five of the seven failures were associated with a combination of smoking and bruxism. Mean marginal bone loss at 20 years was 0.543 ± 1.193 mm (PubMed 38607359). An earlier report from the same lineage followed 121 TiUnite Brånemark implants in 46 patients and recorded 99.2% survival at ten years (PubMed 22642261). These two are the same clinical tradition and should not be counted as independent evidence.

Two further records study the anodised surface without naming a brand. A retrospective analysis of 129 single-tooth implants placed at the Brånemark Clinic in Gothenburg in 2003 and 2004, mean follow-up 13.4 ± 4.8 years, reported a 15-year cumulative survival of 97.4% (PubMed 36773332). A meta-analysis of eight observational studies summarised cumulative survival for anodised surfaces at 0.98 (PubMed 36582952). Neither names the manufacturer in its abstract, so both are surface-class evidence, not brand evidence.

Survival and success are also not the same measurement, a distinction set out in the systematic review of success criteria in implant dentistry (PubMed 22157097) and worked through in detail on our Straumann spec page. Every figure on this page is a survival figure.

/ The marginal bone loss finding, and what the manufacturer did about it

This section is not favourable to the brand, which is exactly why it is here. A neutral spec sheet rules out running a brand down and rules out talking one up, and omitting a measured finding would be the second thing.

A systematic review and meta-analysis compared marginal bone level change across three premium surfaces: Astra Tech OsseoSpeed, Straumann SLA and SLActive, and Nobel Biocare TiUnite. It included 37, 23 and 53 publications respectively. At five years, weighted mean bone loss was 0.35 mm for Astra Tech across 1,168 implants, 0.74 mm for Straumann across 202 implants, and 1.19 mm for TiUnite across 1,683 implants. The difference between Astra Tech and TiUnite was statistically significant (P = .0240). The difference between Straumann and TiUnite was not (P = .0769). The authors concluded that the three surface preparations differed significantly and that the Astra Tech surface showed superior marginal bone maintenance (PubMed 33270049).

The boundaries of that finding belong with it. What was measured is bone level change, not implant loss, and survival for the same surface remained high over the same period. On peri-implantitis, the TiUnite meta-analysis reported a patient-level prevalence of 5.20%, but that figure comes from a mean follow-up of 47.89 months (PubMed 28708905) and cannot be read directly against the 22% weighted mean prevalence calculated for the general implant population (PubMed 25495683), because the follow-up windows and case definitions differ.

The manufacturer's response to this literature was to change the surface. The graded TiUltra design, with a markedly smoother collar zone, reached the market around the period this meta-analysis was published. Whether that changes bone behaviour has not been shown, which is the subject of the next section. What a patient should take from this is not a verdict on the brand but a question for the clinic: which surface is being placed, and why that one.

/ How much clinical evidence TiUltra itself has

A renewed surface is not evidence that the renewal worked. What exists for TiUltra today is small enough to count.

PubMed indexes five records with TiUltra in the title or abstract. Only one is a clinical study: a proof-of-concept prospective series in which 60 TiUltra implants, 32 NobelParallel TiUltra and 28 NobelActive TiUltra, were placed in 10 patients and followed for a mean of 16.2 ± 1.7 months. One implant failed, cumulative success was 98.3%, and mean marginal bone loss was 0.53 ± 0.28 mm (PubMed 33470044). Ten patients at sixteen months cannot be read on the same axis as 46 patients at twenty years.

The remaining four are not clinical. The only study comparing TiUltra directly against TiUnite is a three-dimensional cell culture experiment, which found higher osteogenic gene expression in the TiUltra group and no difference in cell viability or proliferation (PubMed 40096517). On wettability, an independent laboratory measured contact angles on 15 implants and reported that BTI UniCa, Nobel TiUltra and Straumann Roxolid SLActive showed the highest hydrophilicity of the group tested (PubMed 40333410). That is a measurement of a surface property. "Integrates faster" is a claim about outcomes, and these studies do not demonstrate it.

The honest summary is that the long-term evidence behind the surface being placed today is the evidence for the previous surface. This is not specific to this manufacturer; every surface generation has the same calendar problem, and any brand claiming otherwise is claiming something it cannot have. The decision-relevant question is which line and which surface your clinic places, and whether that appears on your quote.

/ The connection: internal conical with a hex index, and no published cone angle

The interface between fixture and abutment is the least discussed technical difference between systems, and it is the variable most often linked to long-term marginal bone behaviour.

Across the mainstream Nobel Biocare lines the connection is an internal conical connection combined with a hex index. The device description in K202344 reads verbatim: "an internal conical connection (CC) with hex interface". The same filing lists platforms as NP, RP and WP, diameters from 3.0 to 5.5 mm and lengths from 6.5 to 18 mm. The manufacturer's prosthetic manual adds built-in platform shifting.

One line is a separate family. The N1 instructions for use describe a "trioval conical connection (TCC)" with a three-lobed coronal zone, so if your clinic places N1 the connection line on your paperwork should read differently from the CC lines.

There is also something deliberately absent here. A cone angle of 12 degrees circulates widely online for this system. It was searched for in three documents and found in none: the NobelParallel CC manual, the K202344 FDA summary and the 2026 instructions for use. Every degree value in K202344 is a prosthetic angulation (0, 17 and 30 degrees for abutments). The 45 and 25 degree "bevel angle" column in the manual describes the implant neck chamfer, not the internal cone. An unverifiable number is worse than a blank, so this page leaves it blank.

The measured effect of connection type is brand-independent. A network meta-analysis of randomised clinical trials found conical interfaces produced less marginal bone loss and fewer prosthetic complications than external hexagonal connections, while finding no significant difference between connection types in survival or biological complication rates (PubMed 34776267).

/ All-on-4 is a Nobel Biocare trademark, but Nobel Biocare did not invent it

The most repeated factual error about this brand is the sentence "Nobel Biocare invented All-on-4 in 1998". Both the inventor and the date are wrong.

The All-on-4 treatment concept was developed by Dr Paulo Maló in the early 1990s. The first patient documented in the first scientific study was treated in 1998. Nobel Biocare's role was support and scale rather than invention: the company backed the work through Dr Bo Rangert and launched the concept commercially in 2004. Those dates come from the manufacturer's own announcement. All-on-4 is today a registered trademark of Nobel Biocare Services AG, as are TiUnite, TiUltra, NobelActive, NobelParallel, NobelReplace, NobelPearl, NobelProcera and NobelZygoma.

The practical consequence is that the trademark attaches to the name, not to the evidence. The clinical record for full-arch rehabilitation on four implants is brand-independent. A systematic review and meta-analysis pooling 55 studies reported survival of 99.20% at one year, 99.66% between one and five years, and 98.14% at five years and beyond for four-implant arches, against 100%, 98.55% and 97.50% for six-implant arches. Marginal bone loss at five years was 1.28 mm and 0.94 mm respectively. The authors' own caution is that heterogeneity between studies was high and the conclusions should be read carefully (PubMed 42031576).

Very long follow-ups exist too, and they come from the clinic that developed the concept. In the maxilla, 4,288 implants in 1,072 patients reported cumulative implant survival of 94.7% with up to 13 years of follow-up (PubMed 30924250). In the mandible, 724 implants in 181 patients with a mean follow-up of 264 months reported 90% implant and 92% prosthetic survival out to 25 years, although 100 of the 181 patients were lost to follow-up and the authors declare funding and speaker relationships with Nobel Biocare Services AG (PubMed 41354261). Neither abstract names the implant system, so both are cited here as concept data rather than brand survival. Our full-mouth implant guide covers what these protocols involve in practice.

/ What a Nobel Biocare implant costs and what actually moves the number

nobel biocare implant cost is the money query for this brand, and the honest answer is a structure rather than a single figure. No price is published on this page, because a number quoted before a CBCT scan describes a product rather than your treatment, and because published clinic figures for this brand vary by several multiples with no methodology attached.

Six layers set the total. The first is the fixture itself, and the brand name alone does not define it: which line (N1, NobelActive, NobelParallel CC, NobelReplace CC, NobelZygoma), which diameter and length within the 3.0 to 5.5 mm and 6.5 to 18 mm ranges, which surface, which platform. The second is the number of stages and what is included, since a fixture price is not a treatment price once a healing abutment, a final abutment and a restoration are added. On1 base components, where used, are a further line.

The third layer is the restoration, chosen independently of the implant system. A zirconia implant crown and other materials move the total on their own, and our dental crown guide for Istanbul sets out the material choices. The fourth is additional surgery: insufficient bone volume means grafting, a low sinus floor in the posterior maxilla means sinus augmentation, and advanced maxillary atrophy may mean zygomatic anchorage, each of which is a separate item that imaging decides.

The fifth is the scale of the case, which changes surgical time and laboratory work by an order of magnitude between a single molar implant, an implant-supported prosthesis and a full-mouth reconstruction. The sixth never appears on the quote at all: component availability, warranty scope and the annual review schedule. Our general implant pricing structure page covers the layers common to every system, and a written itemised quote after examination is the only version worth comparing between clinics. Book a consultation and ask for it line by line.

/ Why UK and US price comparisons are rarely like for like

Search data shows the same pattern in both markets: patients compare locally before they consider treatment abroad, with queries like nobel biocare implant price uk and city-level variants. The comparison is worth making, but only if the baseline is understood.

In the United Kingdom the NHS publishes fixed treatment charges in three bands: £27.90 for band 1, £76.60 for band 2 and £332.10 for band 3. The examples the NHS lists under band 3 are crowns, dentures and bridges. Dental implants are not named among them, so for most patients an implant in the UK is a private fee that the published NHS band table does not describe at all. That is the reason a UK patient cannot anchor on an official number the way they can for a crown.

The second reason comparisons drift is that quotes are rarely itemised the same way. One clinic's figure may cover the fixture only, another's the fixture and abutment, another's the entire restored unit, and a fourth may quote a full-arch package with a temporary prosthesis included. Before comparing any two numbers, confirm which of these six things each covers: fixture, healing abutment, final abutment, restoration, imaging and follow-up reviews.

The third reason is that additional surgery is genuinely unpredictable before imaging. A quote that includes grafting and a quote that excludes it are not competing offers; they are answers to different clinical questions. Our guide to dental implants in Istanbul sets out how the trip is structured, and treatment planning determines which of these items apply to you before any figure is meaningful.

/ The Nobel Biocare warranty: what it covers, and who it is issued to

This is the section that competing pages skip, and it is the one that decides your experience five years from now. The manufacturer's own published terms differ from what most clinics imply.

The coverage reads as follows. An implant that fails to remain in bone is replaced under a lifetime warranty. Non-temporary, non-provisional restorative components carry lifetime coverage. Abutments placed on a non-Nobel Biocare implant are limited to ten years from the date of placement. NobelProcera products are region-dependent: the international page states five years, while the US page states ten years for products purchased after 1 February 2023. So "the Nobel warranty" is not one document but a set of regional documents, and the one that applies to you is the one covering the market where the product was purchased.

The decisive point is not duration but the beneficiary. The warranty is issued to eligible treatment providers, defined by the manufacturer as dentists, physicians and dental technicians. It is not issued to the patient. The exclusions are equally explicit: trauma and patient-caused damage, temporary implant systems, custom-modified products, attachments and riders for implant bars, and every cost beyond product replacement. Surgical fees, laboratory costs and treatment expenses are outside the warranty. Using non-original components voids coverage entirely.

The practical translation is short. Lifetime replacement is real, and it covers the screw, not the operation. The procedure to place a replacement is covered by the clinic's own guarantee, which is a separate document with its own duration and its own exclusions. Ask for both in writing before treatment starts, not after. We issue ours at the treatment planning stage, and our clinical team will explain what each one does and does not include.

/ The warranty form patients keep searching for

Search suggestions in both the UK and the US return nobel biocare implant warranty form alongside nobel biocare implant warranty. That pairing tells you something specific: patients are not merely curious about the warranty, they are trying to claim it themselves.

They usually cannot, and the reason is structural rather than obstructive. Because the warranty is issued to the treatment provider, the claim is filed by the clinic that placed the implant, using its own account with the manufacturer, referencing the product's lot and reference numbers. A patient submitting a form directly has no account to file against. If you have lost contact with the original clinic, the route back runs through your implant card and a new provider willing to file on your behalf, not through a form you complete yourself.

There is one documented exception worth knowing. The manufacturer issues a patient-facing guarantee for NobelProcera implant bar overdentures, delivered as a Patient Guarantee Card. If your restoration is that specific product type, you should have received a card, and it is worth asking for it if you did not.

Everything else is an argument for keeping the paperwork. Three documents make any future claim possible: the implant card with the serial, lot and unique device identification numbers, the itemised treatment record showing which line and surface were placed, and the clinic's written guarantee. Our patient journey page lists what is handed over at discharge, and the gum and implant maintenance schedule explains what keeps the clinical side of that guarantee valid.

/ The implant card, traceability and confirming you received what you paid for

Counterfeit and grey-market implants are a real risk category, and the narrative around it is currently written mostly by clinics outside Turkey. The productive response is not a denial but a verification procedure any patient can run in five minutes.

European medical device law requires the manufacturer of an implantable device to supply an implant card and specifies what it must carry: device name, serial number, lot number, Unique Device Identification, model, and the manufacturer's name and address, together with information on the expected lifetime of the device and any necessary follow-up care (Regulation (EU) 2017/745, Article 18). That card is what makes a claim checkable.

Three checks follow. Confirm that the serial or lot number on the card matches the sticker peeled from the sterile packaging, which is normally attached to your record during surgery. Confirm that the line and surface written down form a real combination, since names pair in specific ways such as NobelActive TiUltra or NobelParallel CC TiUnite. And confirm the manufacturer name is one of the two legal entities, Nobel Biocare AB or Nobel Biocare Services AG, rather than a distributor trade name.

One point about service after you fly home should be stated plainly rather than assumed. The manufacturer's own region selector does not carry a Turkey page. That does not mean the product is unavailable in Turkey, but it does mean the component supply and service chain should be confirmed with the clinic in writing rather than inferred. Ask who supplies replacement components, and whether a dentist in your own country can order them against the product codes on your card. Our contact page is the right place to put that question before treatment, not after.

/ NobelPearl, the metal-free option, and its limits

For patients who do not want titanium, the brand has a separate line, and its evidence base is not the same as the titanium lines.

NobelPearl is a two-piece ceramic implant milled from hot isostatic-pressed alumina-toughened zirconia. The connecting screw is metal-free as well: a carbon fibre reinforced polymer screw marketed as VICARBO. So the system is genuinely metal-free rather than metal-free only where it shows.

The evidence has to be described honestly. No clinical survival study published under this product name could be found in PubMed. The closest evidence is at class level: a systematic review and meta-analysis of zirconia implants covering 25 studies, 2,083 patients and 4,017 implants reported a 10-year cumulative survival rate of 95.1%. Two of its findings apply directly to this line. Two-piece zirconia implants showed statistically significantly lower survival than one-piece designs (p = 0.017), and of the 172 recorded failures, 26 were implant fractures, mostly in narrow-diameter implants (PubMed 38135804).

There is also a measured difference in wettability. In the contact angle study cited earlier, zirconia implants showed markedly lower hydrophilicity than the premium titanium group, and within that zirconia group Nobel Pearl produced smaller contact angles than the comparator ceramic implant (PubMed 40333410). A metal-free option is a genuine option, and for a patient who wants one it may be the right choice. It is not evidentially equivalent to the titanium lines, and that trade-off belongs on the consent form rather than in a footnote.

/ What decides the ten-year result

how long do nobel biocare implants last invites a number, and the defensible answer is a set of conditions. The clearest signal comes from the 20-year cohort itself, where five of the seven failures were associated with a combination of smoking and bruxism rather than with the implant (PubMed 38607359).

Peri-implant disease is common across all systems. The standing epidemiology review calculates weighted mean prevalences of 43% for peri-implant mucositis and 22% for peri-implantitis, and its meta-regression shows prevalence rising with function time (PubMed 25495683). The longer an implant is in service, the more risk accumulates, which is why a survival figure at ten years and a survival figure at twenty are not interchangeable.

Maintenance is the variable with measured benefit. A systematic review and meta-analysis of maintenance therapy found lower incidence of peri-implant disease among implants enrolled in supportive programmes and concluded that a recall interval of at least five to six months is warranted; the same analysis identified a history of periodontal disease as a significant influence (PubMed 26701350). That is why gum health is settled before implant planning rather than after, and why peri-implantitis and its treatment has its own page here.

Brand choice shapes the first day. Maintenance shapes the tenth year. That holds for this system and for every other one in our comparison table, including Straumann, Osstem, Neodent, Astra Tech, Ankylos and Medentika.

/ Who a Nobel Biocare implant is chosen for

There is no ranking here, only clinical indication. The distinguishing property of this system is the depth of its long-term literature: follow-up data exist at 10, 15 and 20 years, which can be a legitimate reason to choose it when documented long-term predictability is what a case needs.

Indications differ by line. NobelActive's back-tapered coronal design, reverse-cutting flutes and double lead threads are engineered toward primary stability in soft bone and in fresh extraction sockets. NobelParallel CC's parallel walls suit sites where bone volume is limited or adjacent roots are close. NobelReplace CC is the single lead thread tapered line. NobelZygoma addresses advanced maxillary atrophy where a conventional fixture has nothing to anchor into. NobelPearl is reserved for cases where titanium is not wanted, with the evidence limits described above.

The variables that decide are bone volume and density, the position of the edentulous site, the opposing arch, bite load, systemic health and the planned restoration. They are measured with CBCT imaging and clinical examination rather than chosen from a brand list. For a single missing tooth, the prior question is often implant against bridge, and where a case is planned digitally, guided surgery changes how the plan is executed rather than which brand is used.

A statement that one brand is better than another is clinically wrong, because the correct system varies by case. Our clinicians will take you through the specification of whichever system is proposed for you, including the ones that are not on this page.